Lineage Cell Therapeutics: Funding, Investors & Team (Sep 2026)
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cellular therapies to treat unmet medical needs. The company is focused on developing new therapeutics for age-related degenerative disease. BioTime and its subsidiaries are developing OpRegen® (a cell-based therapy for age-related macular degeneration), therapies for cancer, and arthritis, respectively. Our subsidiary ReCyte Therapeutics is using proprietary technology to reverse the developmental aging of human cells to manufacture young vascular progenitors for the treatment of age-related vascular disease. Relatively near-term product development by BioTime and its subsidiaries include Renevia, a patented hyaluronan-based hydrogel device for cell delivery; PanC-Dx, a blood-based pan-cancer screening diagnostic; and re-starting the embryonic stem cell-based clinical trial for spinal cord injury that was originally begun by Geron, using the stem cell assets acquired from them in 2013. BioTime also markets an FDA-approved blood plasma expander called Hextend®, which is currently marketed in collaboration with Hospira.
Lineage Cell Therapeutics has raised $92.0M across 4 funding rounds on record, the most recent an undisclosed round of $12.0M announced in Aug 2025.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Lineage Cell Therapeutics Company Profile and Key Stats
Latest funding round on record: Aug 2025.
Lineage Cell Therapeutics Funding Rounds
1 of 4 rounds was announced without a disclosed amount and is excluded from the total.
Lineage Cell Therapeutics announced an undisclosed round in May 2023; the amount was not disclosed.
9 months later, an undisclosed round of $14.0M was announced in Feb 2024.
9 months later, an undisclosed round of $66.0M was announced in Nov 2024.
9 months later, an undisclosed round of $12.0M was announced in Aug 2025.
Lineage Cell Therapeutics Founders and Leadership Team
No contact details are on record for this team yet.
Lineage Cell Therapeutics Funding Compared to Other Biotechnology Startups
Lineage Cell Therapeutics' latest round of $12.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Lineage Cell Therapeutics in Biotechnology and Carlsbad
Companies Similar to Lineage Cell Therapeutics
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
Lineage Cell Therapeutics Funding FAQs
What does Lineage Cell Therapeutics do?
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cellular therapies to treat unmet medical needs. The company is focused on developing new therapeutics for age-related degenerative disease. BioTime and its subsidiaries are developing OpRegen® (a cell-based therapy for age-related macular degeneration), therapies for cancer, and arthritis, respectively. Our subsidiary ReCyte Therapeutics is using proprietary technology to reverse the developmental aging of human cells to manufacture young vascular progenitors for the treatment of age-related vascular disease. Relatively near-term product development by BioTime and its subsidiaries include Renevia, a patented hyaluronan-based hydrogel device for cell delivery; PanC-Dx, a blood-based pan-cancer screening diagnostic; and re-starting the embryonic stem cell-based clinical trial for spinal cord injury that was originally begun by Geron, using the stem cell assets acquired from them in 2013. BioTime also markets an FDA-approved blood plasma expander called Hextend®, which is currently marketed in collaboration with Hospira.
How much funding has Lineage Cell Therapeutics raised?
Lineage Cell Therapeutics has raised $92.0M across 4 rounds on record. The most recent is an undisclosed round of $12.0M announced in Aug 2025.
When did Lineage Cell Therapeutics last raise funding?
Lineage Cell Therapeutics' most recent funding round on record is an undisclosed round of $12.0M, announced in Aug 2025.
Who founded Lineage Cell Therapeutics?
FundedIQ lists Paul Segall (Founder) at Lineage Cell Therapeutics.
Who is the CEO of Lineage Cell Therapeutics?
Brian M Culley is listed as CEO at Lineage Cell Therapeutics.
Where is Lineage Cell Therapeutics headquartered?
Lineage Cell Therapeutics is based in Carlsbad, California, United States.
How many employees does Lineage Cell Therapeutics have?
Lineage Cell Therapeutics is in the 101-250 employee band.
How does Lineage Cell Therapeutics' funding compare to other Biotechnology startups?
Lineage Cell Therapeutics' latest round of $12.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Lineage Cell Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Lineage Cell Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.